Literature DB >> 7862953

Effects of SR 48692, a selective non-peptide neurotensin receptor antagonist, on two dopamine-dependent behavioural responses in mice and rats.

M Poncelet1, J Souilhac, C Gueudet, J P Terranova, D Gully, G Le Fur, P Soubrié.   

Abstract

One major mechanism underlying the central action of neurotensin is an interaction with the function of dopamine (DA)-containing neurons. In addition, direct or indirect DA agonists have been reported to promote neurotensin release. We have found that SR 48692, a non-peptide neurotensin receptor antagonist (0.04-0.64 mg/kg orally), antagonizes (50-65%) yawning induced by apomorphine (0.07 mg/kg SC) or bromocriptine (2 mg/kg IP) in rats, and turning behaviour induced by intrastriatal injection of apomorphine (0.25 micrograms), (+) SKF 38393 (0.1 micrograms), bromocriptine (0.01 ng) or (+) amphetamine (10 micrograms) in mice. Other apomorphine-induced effects in mice and rats such as climbing, hypothermia, hypo- and hyper-locomotion, penile erections and stereotypies were not significantly modified by SR 48692. Taken together, these data suggest that neurotensin may play a permissive role in the expression of some but not all behavioural responses to DA receptor stimulation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7862953     DOI: 10.1007/bf02245067

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  27 in total

1.  Neurotensin counteracts apomorphine-induced inhibition of dopamine release as studied by microdialysis in rat neostriatum.

Authors:  S Tanganelli; G von Euler; K Fuxe; L F Agnati; U Ungerstedt
Journal:  Brain Res       Date:  1989-11-20       Impact factor: 3.252

2.  Effects of dopamine autoreceptor stimulation on the release of colocalized transmitters: in vivo release of dopamine and neurotensin from rat prefrontal cortex.

Authors:  A J Bean; M J During; R H Roth
Journal:  Neurosci Lett       Date:  1990-01-01       Impact factor: 3.046

3.  Antagonism of apomorphine-induced yawning by SCH 23390: evidence against the autoreceptor hypothesis.

Authors:  M Morelli; R Longoni; L Spina; G Di Chiara
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  Neurotensin causes a greater increase in the metabolism of dopamine in the accumbens than in the striatum in vivo.

Authors:  R Rivest; F B Jolicoeur; C A Marsden
Journal:  Neuropharmacology       Date:  1991-01       Impact factor: 5.250

5.  Neurotensin-dopamine interactions in the substantia nigra of the rat brain.

Authors:  K M Merchant; L G Bush; J W Gibb; G R Hanson
Journal:  J Pharmacol Exp Ther       Date:  1990-11       Impact factor: 4.030

6.  Inhibition of apomorphine-induced yawning and penile erection by neurotensin.

Authors:  D Nouel; J Costentin
Journal:  Peptides       Date:  1991 Jul-Aug       Impact factor: 3.750

7.  Inhibitory effect of morphine on yawning induced by cholinoceptor and dopamine D2 receptor activation in rats.

Authors:  M R Zarrindast; A Jamshidzadeh
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

8.  Neuropharmacological profile of a novel and selective ligand of the sigma site: SR 31742A.

Authors:  M Poncelet; V Santucci; R Paul; C Gueudet; S Lavastre; J Guitard; R Steinberg; J P Terranova; J C Brelière; P Soubrié
Journal:  Neuropharmacology       Date:  1993-06       Impact factor: 5.250

9.  Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor.

Authors:  D Gully; M Canton; R Boigegrain; F Jeanjean; J C Molimard; M Poncelet; C Gueudet; M Heaulme; R Leyris; A Brouard
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

10.  Turning behavior induced by intrastriatal injection of neurotensin in mice: sensitivity to non-peptide neurotensin antagonists.

Authors:  M Poncelet; C Gueudet; D Gully; P Soubrié; G Le Fur
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-01       Impact factor: 3.000

View more
  3 in total

1.  Role of endogenous neurotensin in the behavioral and neuroendocrine effects of cocaine.

Authors:  C Betancur; R Cabrera; E R de Kloet; D Pélaprat; W Rostène
Journal:  Neuropsychopharmacology       Date:  1998-10       Impact factor: 7.853

2.  The role of endogenous neurotensin in psychostimulant-induced disruption of prepulse inhibition and locomotion.

Authors:  Ricardo Cáceda; Elisabeth B Binder; Becky Kinkead; Charles B Nemeroff
Journal:  Schizophr Res       Date:  2011-11-21       Impact factor: 4.939

3.  Striatal dopamine receptor plasticity in neurotensin deficient mice.

Authors:  Lucy G Chastain; Hongyan Qu; Chase H Bourke; P Michael Iuvone; Paul R Dobner; Charles B Nemeroff; Becky Kinkead
Journal:  Behav Brain Res       Date:  2014-11-15       Impact factor: 3.332

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.